Printer Friendly

Amryt signs contract with Aegerion Pharmaceuticals.

M2 EQUITYBITES-May 14, 2018-Amryt signs contract with Aegerion Pharmaceuticals

(C)2018 M2 COMMUNICATIONS http://www.m2.com

United Kingdom-based Amryt has signed a contract with Japan-based Aegerion Pharmaceuticals, it was reported on Friday.

The contract has been signed to expand Aegerion's exclusive licence agreement for Lojuxta (lomitapide), an approved treatment for adult patients with the rare cholesterol disorder Homozygous Familial Hypercholesterolaemia (HoFH), into Russia and the Commonwealth of Independent States (CIS) and the non-EU Balkan states.

Amryt estimates there is likely to be up to 450 additional patients who could benefit from treatment with Lojuxta across the countries covered by the extended agreement, representing an increase of around 25 percent in the total number of addressable patients in the Amryt territories. Amryt is actively seeking distribution partners in these new territories.

This licence expansion extends the original agreement, received in December 2016, which includes the European Economic Area, Middle East and North Africa, Switzerland, Turkey and Israel. Under this agreement Amryt will formally become the Marketing Authorisation holder for Lojuxta in Europe, which will marginally increase the level of royalties payable to Aegerion.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:May 14, 2018
Words:194
Previous Article:Accenture develops new digital asset management system for Shaanxi Electric.
Next Article:R2 Venture Closes Acquisition of Consumer Durable Goods Wholesaler Townecraft.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters